During the 2024 edition of the breast cancer debate of the year, an esteemed panel of breast cancer experts addressed several unanswered questions in the care for patients with early-stage breast cancer (EBC). In three pro-con sessions, the experts respectively discussed the current indication for anthracyclines in chemotherapy regimens for patients with EBC, tackled the need for an axillary lymph node dissection (ALND) in the contemporary management of EBC patients and discussed the feasibility of de-escalating chemotherapy in patients with stage I triple negative breast cancer (TNBC). In addition to these interesting debates, the breast cancer debate of the year featured a critical review of the clinical trial data supporting the use of CDK4/6 inhibitors in the adjuvant treatment of patients with hormone-receptor positive, HER2-negative EBC.